Answers are grounded in this paper and cite their sources.
An analysis of published studies suggests that a longer duration of immune checkpoint inhibitor therapy is associated with a higher incidence of complete response among patients with mismatch repair–deficient cancers.
No takes yet. Share an insight, caveat, or question.
Rousseau et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: